AbCellera to present Phase 1/2 safety, PK, PD and efficacy data for ABCL635 at TMS 2026 Annual Meeting

AbCellera announced it will present safety, pharmacokinetics, pharmacodynamics and efficacy data from its Phase 1/2 trial of ABCL635 at the TMS 2026 Annual Meeting, including new safety data from the Phase 1 multiple ascending dose study and new patient-reported outcome data from the Phase 2 study.

Detected & updated continuously · Source: Nebula